Press Releases :: Nighthawk Biosciences, Inc. (NHWK)

Apr 19, 2022 11:00am EDT

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

Apr 18, 2022 4:00pm EDT

REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments

Apr 18, 2022 8:30am EDT

Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

Apr 14, 2022 12:35pm EDT

Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

Mar 25, 2022 8:00am EDT

Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

Mar 23, 2022 8:30am EDT

Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

Mar 14, 2022 8:00am EDT

Heat Biologics Provides Year-End 2021 Business Update

Feb 02, 2022 4:05pm EST

Heat Biologics Announces Planned Transfer to the NYSE American

Jan 31, 2022 7:30am EST

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Jan 12, 2022 8:00am EST

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

rss_feed News RSS

OUR ECOSYSTEM